Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials

Monami, Matteo; Filippi, Luca; Ungar, Andrea; Sgrilli, F.; Antenore, Alessandro; Dicembrini, Ilaria; Bagnoli, Paola; Marchionni, Niccolò; Rotella, Carlo Maria; Mannucci, Edoardo

doi:10.1185/03007995.2013.772505

Cited by 40 publications

(25 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, although controversial results have also been reported [35], the use of β-blockers may reduce the mortality of lung, breast, ovary, and prostate cancer [36–40]. Although the correlation between the use of β-blockers and the reduction of cancer risk remains questionable and needs to be further investigated [41, 42], our results provide preclinical evidence for using β-AR antagonists in prevention of smoking-associated lung cancer. In addition, previous studies have reported a possible positive correlation between hypertension and lung cancer in current smokers [43, 44].…”

Section: Discussionmentioning

confidence: 64%

Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation

et al. 2016

View full text Add to dashboard Cite

Activation of receptor tyrosine kinases (RTKs) is associated with carcinogenesis, but its contribution to smoking-associated lung carcinogenesis is poorly understood. Here we show that a tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced insulin-like growth factor 1 receptor (IGF-1R) activation via β-adrenergic receptor (β-AR) is crucial for smoking-associated lung carcinogenesis. Treatment with NNK stimulated the IGF-1R signaling pathway in a time- and dose-dependent manner, which was suppressed by pharmacological or genomic blockade of β-AR and the downstream signaling including a Gβγ subunit of β-AR and phospholipase C (PLC). Consistently, β-AR agonists led to increased IGF-1R phosphorylation. The increase in IGF2 transcription via β-AR, signal transducer and activator of transcription 3 (STAT3), and nuclear factor-kappa B (NF-κB) was associated with NNK-induced IGF-1R activation. Finally, treatment with β-AR antagonists suppressed the acquisition of transformed phenotypes in lung epithelial cells and lung tumor formation in mice. These results suggest that blocking β-AR-mediated IGF-1R activation can be an effective strategy for lung cancer prevention in smokers.

show abstract

Section: Discussionmentioning

confidence: 64%

Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Even, in diabetic patients a significantly reduced overall risk of cancer has been reported with β-blocker use (Monami et al, 2013). However, in a retrospective study using UK's primary care database, Shah et al (2011) compared the survival rate of newly diagnosed cancer (solid tumors) patients who were regularly treated with β-blockers before the diagnosis with those who received other antihypertensive drugs, and reported a poor effect of β-blockers on survival.…”

Section: Clinical Observations and Retrospective Studiesmentioning

confidence: 99%

Are Beta Blockers New Potential Anticancer Agents?

Akbar¹,

Alsharidah²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…This hypothesis is based on various research studies, most of them observational or experiments in animal models, which have reported a decreased overall risk of cancer, reduced metastasis, and less tumor recurrence; moreover, increased overall disease-free survival has been observed among patients with cancer who were taking b-blockers for other reasons. [8][9][10][11] This effect may be because b-adrenergic receptors are related to the inhibition of multiple intracellular processes involved in the progression and metastasis of different cancers, in the invasion of the extracellular matrix, in the expression of proinflammatory cytokines, in tumor immune responses, and, presumably, in angiogenesis. [8][9][10][11] Moreover, if the present case is considered multifocal infantile hemangioma, it would be the first reported case to be treated (and achieving a good response) with propranolol.…”

Section: Figurementioning

confidence: 99%

Delayed-Onset of Multiple Cutaneous Infantile Hemangiomas Due to Propranolol: A Case Report

2015

View full text Add to dashboard Cite

Infantile hemangiomas are the most common vascular tumors in childhood. In view of its proven effectiveness in such cases, propranolol is the drug of choice. We present the case of a male infant who started treatment with propranolol shortly after birth due to heart disease. After 7 months, when the patient had suffered various respiratory exacerbations, this treatment was suspended. One week later, multiple skin lesions (ie, multifocal infantile hemangiomas) began to appear, with no extracutaneous involvement. It was decided to resume treatment with propranolol, although at lower doses than before, and the skin lesions improved rapidly, with some disappearing completely. Treatment was definitively withdrawn at age 16 months, with only slight recurrence of the lesions. The case described is of multifocal infantile hemangiomas without extracutaneous involvement appearing beyond the neonatal period after treatment with propranolol beginning in the first days of life. The details of the case support the hypothesis that this drug is not only therapeutic but also plays a prophylactic role against infantile hemangiomas. In turn, this supports the recent proposal that this drug may be useful in preventing the growth and spread of tumors with high angiogenic potential. It is postulated that the inhibition of β-adrenergic receptors is associated with multiple intracellular processes related to the progression and metastasis of different tumors.

show abstract

Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials

Abstract: In conclusion, this research seem to confirm a possible beneficial effect of β-blockers against the risk of cancer development.

Cited by 40 publications

References 60 publications

Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation

Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation

Are Beta Blockers New Potential Anticancer Agents?

Delayed-Onset of Multiple Cutaneous Infantile Hemangiomas Due to Propranolol: A Case Report

Contact Info

Product

Resources

About